Good Review Management Guidance Focuses On PDUFA Sponsor Involvement
This article was originally published in The Tan Sheet
Executive Summary
Responsibility for pre-submission phase management during drug development remains with the sponsor, FDA reiterates in its final Good Review Management Principles guidance on PDUFA products
You may also be interested in...
FDA Defines Good Review Management; No Data In Labeling Negotiations
Last-minute labeling negotiations are not an appropriate time for presentation of additional data by NDA sponsors, FDA said in a draft guidance on review practices
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands